Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Camilla R MadeiraFernanda Stumpf ToninMariana Millan FachiHelena Hiemisch Lobo BorbaVinicius Lins FerreiraLetícia P LeonartAline F BonettiRogerio P MoritzAngela C L B TrindadeAlan G GonçalvesFernando Fernandez-LllimosRoberto PontaroloPublished in: World journal of urology (2020)
Sildenafil at low doses and tadalafil should be the first therapeutic options. Avanafil, lodenafil and mirodenafil use are hardly justified given the lack of expressive efficacy or high rates of adverse events.